The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT04825990
Brief Title: Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer (POINT)
First Submitted : March 29, 2021
First Submitted that Met QC Criteria : March 29, 2021
First Posted : April 1, 2021
Last Update Submitted that Met QC Criteria : March 29, 2022
Last Update Posted : April 7, 2022